The impact of statins on psychological wellbeing: a systematic review and meta-analysis

BMC Medicine

Michael Berk⁴  Julie A Pasco¹  Lana J Williams⁶  Felice Jacka⁶  Kristy Sanderson²  Cassie Redlich⁵  Livia Sanna³  Adrienne O'Neil⁷ 

[1] Barwon Epidemiology and Biostatistics Unit, Deakin University, Geelong, Victoria, Australia;Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia;Unit of Psychiatry, Neuroscience Mental Health and Sensory Organs Department (NeSMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy;School of Medicine, Deakin University, Geelong, Victoria, Australia;Masters Programme in Public Health, Department of Clinical Sciences, Social Medicine and Global Health, Lund University, Lund, Sweden;Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia;School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

关键词: statins;    oxidative;    mood;    hypercholesterolemia;    depression;    cytokines;    anti-inflammatory;   

Others  :  857271
DOI  :  10.1186/1741-7015-10-154

 received in 2012-05-25, accepted in 2012-12-03,  发布年份 2012

【 摘 要 】

Background

Cholesterol-lowering medications such as statins have anti-inflammatory and antioxidant properties, which may be beneficial for treating depression and improving mood. However, evidence regarding their effects remains inconsistent, with some studies reporting links to mood disturbances. We aimed to conduct a meta-analysis to determine the impact of statins on psychological wellbeing of individuals with or without hypercholesterolemia.

Methods

Articles were identified using medical, health, psychiatric and social science databases, evaluated for quality, and data were synthesized and analyzed in RevMan-5 software using a random effects model.

Results

The 7 randomized controlled trials included in the analysis represented 2,105 participants. A test for overall effect demonstrated no statistically significant differences in psychological wellbeing between participants receiving statins or a placebo (standardized mean difference (SMD) = -0.08, 95% CI -0.29 to 0.12; P = 0.42). Sensitivity analyses were conducted to separately analyze depression (n = 5) and mood (n = 2) outcomes; statins were associated with statistically significant improvements in mood scores (SMD = -0.43, 95% CI -0.61 to -0.24).

Conclusions

Our findings refute evidence of negative effects of statins on psychological outcomes, providing some support for mood-related benefits. Future studies could examine the effects of statins in depressed populations.

【 授权许可】

   
2012 O'Neil et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F: The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001, 131:41-46.
• [2]Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
• [3]Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994, 344:1383-1389.
• [4]Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
• [5]Olson MB, Kelsey SF, Matthews KA, Bairey MERZ N, Eteiba W, McGorray SP, Cornell CE, Vido DA, Muldoon MF: Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study. J Womens Health 2008, 17:187-194.
• [6]Zureik M, Courbon D, Ducimetiere P: Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996, 313:649-651.
• [7]Engelberg H: Low serum cholesterol and suicide. Lancet 1992, 339:727-729.
• [8]Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM: Long-term statin use and psychological well-being. J Am Coll Cardiol 2003, 42:690-697.
• [9]Ormiston T, Wolkowitz OM, Reus VI, Manfredi F: Behavioral implications of lowering cholesterol levels: a double-blind pilot study. Psychosomatics 2003, 44:412-414.
• [10]Stafford L, Berk M: The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011, 72:1229-1235.
• [11]Otte C, Zhao S, Whooley MA: Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the heart and soul study. J Clin Psychiatry 2012, 73:610-615.
• [12]Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA, Berk M: Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010, 79:323-325.
• [13]While A, Keen L: The effects of statins on mood: a review of the literature. Eur J Cardiovasc Nurs 2012, 11:85-96.
• [14]Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009, 338:b2376.
• [15]Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas J-P, Ebrahim S: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, 12:CD008203.
• [16]Curtin F, Altman DG, Elbourne D: Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med 2002, 21:2131-2144.
• [17]Follmann D, Elliot P, Suh I, Cutler J: Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992, 45:769-773.
• [18]Hozo S, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13. BioMed Central Full Text
• [19]Hyyppa M, Kronholm E, Virtanen A, Leino A, Jula A: Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 2003, 28:181-194.
• [20]Derogatis L, Melisaratos N: The Brief Symptom Inventory: an introductory report. Psychol Med 1983, 13:595-605.
• [21]Moher D, Liberati A, Tetzlaff J, Altman D: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
• [22]Downs JR, Oster G, Santanello NC, the Air Force Coronary Atherosclerosis Prevention Study Research G: HMG CoA reductase inhibitors and quality of life. JAMA 1993, 269:3107-3108.
• [23]Wardle J, Armitage J, Collins R, Wallendszus K, Keech A, Lawson A: Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. BMJ 1996, 313:75-78.
• [24]Harrison RW, Ashton CH: Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994, 37:231-236.
• [25]Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C: Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995, 18:209-214.
• [26]Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J, for the LSI: Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. Arch Intern Med 2000, 160:3144-3152.
• [27]Morales K, Wittink M, Datto C, DiFilippo S, Cary M, TenHave T, Katz IR: Simvastatin causes changes in affective processes in elderly volunteers. J Am Geriatr Soc 2006, 54:70-76.
• [28]Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck SB: Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000, 108:538-546.
• [29]Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
• [30]Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461:25-46.
• [31]Pasco J, Nicholson G, Ng F, Henry M, Williams L, Kotowicz M, Hodge J, Dodd S, Kapczinski F, Gama C, Berk M: Oxidative stress may be a common mechanism linking major depression and osteoporosis. Acta Neuropsychiatrica 2008, 20:112-116.
• [32]Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M: New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
• [33]Yang C, Jick S, Jick H: Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003, 163:1926-1932.
• [34]O'Neil A, Williams ED, Stevenson CE, Oldenburg B, Berk M, Sanderson K: Co-morbid cardiovascular disease and depression: sequence of disease onset is linked to mental but not physical self-rated health. Results from a cross-sectional, population-based study. Soc Psychiatry Psychiatr Epidemiol 2012, 47:1145-1151.
• [35]Terrin N: In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005, 58:894-901.